Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.43 |
| ▸ | FEN1 | P39748 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18419032 | 0.88 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17527387 | 0.88 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31124313 | 0.85 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20183873 | 0.83 | GPR119 (0.51) | SCN9APIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29983203 | 0.80 | JAK1 (0.43) | PIK3CD | |
| SCHEMBL27028318 | 0.80 | JAK1 (0.43) | PIK3CD | |
| SCHEMBL22613074 | 0.78 | BCHE (0.40) | BCHEHTR6PIK3CD | |
| SCHEMBL22613075 | 0.78 | BCHE (0.40) | BCHEHTR6PIK3CD | |
| SCHEMBL20183473 | 0.77 | ACACB (0.36) | SCN9AACACB | |
| SCHEMBL22620109 | 0.77 | HDAC4 (0.40) | BCHEHTR6PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | ALOX5AP 3712/4885FEN1 3292/4885BCHE 4529/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | ALOX5AP 3918/4885FEN1 2552/4885BCHE 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.